We are live on ! Find out more
OPNT

Opiant Pharmaceuticals, Inc. Common Stock
OPNT

Delisted

OPNT was delisted on the 1st of March, 2023.

Back to rankings

32 hedge funds and large institutions have $19.4M invested in Opiant Pharmaceuticals, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 10 increasing their positions, 8 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

25% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 8

3% less funds holding

Funds holding: 33 → 32 (-1)

13% less capital invested

Capital invested by funds: $22.3M → $19.4M (-$2.94M)

25% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 4

Holders
32
Holders Change
-1
Holders Change %
-3.03%
% of All Funds
0.55%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.03%
New
3
Increased
10
Reduced
8
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
MFIM
Mesirow Financial Investment Management
Illinois
+$200K
2
Mariner
Mariner
Kansas
+$154K
3
ACA
Apis Capital Advisors
New York
+$90.7K
4
Wells Fargo
Wells Fargo
California
+$21.4K
5
Northern Trust
Northern Trust
Illinois
+$17K

Top Sellers

Rank Fund Capital Flow
1
Two Sigma Advisers
Two Sigma Advisers
New York
-$578K
2
Renaissance Technologies
Renaissance Technologies
New York
-$187K
3
Two Sigma Investments
Two Sigma Investments
New York
-$174K
4
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
-$168K
5
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$120K
Name Holding Trade Value Shares
Change 		Change in
Stake
HP
1
HealthInvest Partners
Sweden
$2.26M – – –
Wells Fargo
2
Wells Fargo
California
$2.21M +$21.4K +1,886 +0.9%
ACA
3
Apis Capital Advisors
New York
$2.19M +$90.7K +8,000 +4%
Vanguard Group
4
Vanguard Group
Pennsylvania
$2.01M – – –
Renaissance Technologies
5
Renaissance Technologies
New York
$1.9M -$187K -16,500 -9%
SCM
6
Stonepine Capital Management
Oregon
$1.64M – – –
Acadian Asset Management
7
Acadian Asset Management
Massachusetts
$1.36M – – –
Dimensional Fund Advisors
8
Dimensional Fund Advisors
Texas
$1.21M -$168K -14,800 -12%
PHP
9
Parkman Healthcare Partners
Connecticut
$823K +$10.2K +898 +1%
Geode Capital Management
10
Geode Capital Management
Massachusetts
$523K +$1.89K +167 +0.3%
EIM
11
Essex Investment Management
Massachusetts
$507K -$36.7K -3,236 -6%
BlackRock
12
BlackRock
New York
$429K +$1.44K +127 +0.3%
Northern Trust
13
Northern Trust
Illinois
$418K +$17K +1,498 +4%
PCM
14
Perritt Capital Management
Illinois
$328K – – –
Two Sigma Advisers
15
Two Sigma Advisers
New York
$252K -$578K -51,000 -69%
Two Sigma Investments
16
Two Sigma Investments
New York
$234K -$174K -15,326 -41%
Bank of New York Mellon
17
Bank of New York Mellon
New York
$191K +$1.33K +117 +0.7%
MFIM
18
Mesirow Financial Investment Management
Illinois
$190K +$200K +17,633 New
Mariner
19
Mariner
Kansas
$146K +$154K +13,550 New
State Street
20
State Street
Massachusetts
$143K – – –
TI
21
Trexquant Investment
Connecticut
$142K +$11.3K +1,000 +8%
SFI
22
Susquehanna Fundamental Investments
Pennsylvania
$108K +$114K +10,052 New
Morgan Stanley
23
Morgan Stanley
New York
$77K -$17.5K -1,546 -18%
Osaic Holdings
24
Osaic Holdings
Arizona
$62K +$3.4K +300 +5%
UBS Group
25
UBS Group
Switzerland
$16K +$3.02K +266 +23%
1
2

OPNT Hedge Fund Activity: Q3 2022 in Review

32 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Opiant Pharmaceuticals, Inc. Common Stock (OPNT) for Q3 2022, worth a combined $19.4M — down 13% from $22.3M a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of OPNT and 3 opened new positions — a net loss of 1 holder — while 8 trimmed existing stakes and 10 added.

The largest buyer was Mesirow Financial Investment Management, opening a new position worth an estimated $200K. The largest seller was Two Sigma Advisers, cutting an estimated $578K.

  • 32 institutional investors held Opiant Pharmaceuticals, Inc. Common Stock (OPNT) as of Q3 2022, down from 33 in Q2 2022.
  • Funds reported $19.4M of Opiant Pharmaceuticals, Inc. Common Stock stock for Q3 2022, down 13% quarter-over-quarter.
  • 3 funds opened new Opiant Pharmaceuticals, Inc. Common Stock positions in Q3 2022 and 4 closed out, a net change of -1 holder.
  • The largest Opiant Pharmaceuticals, Inc. Common Stock buyer in Q3 2022 was Mesirow Financial Investment Management, an estimated $200K added.
  • The largest Opiant Pharmaceuticals, Inc. Common Stock seller in Q3 2022 was Two Sigma Advisers, an estimated $578K sold.

Based on aggregated 13F filings for Q3 2022.